Regeneron Pharmaceuticals Stock (REGN): $824 Price Target From Goldman Sachs

By Amit Chowdhry ● Dec 6, 2021
  • The shares of Regeneron Pharmaceuticals Inc (NASDAQ: REGN) have received an $824 price target from Goldman Sachs. These are the details.

The shares of Regeneron Pharmaceuticals Inc (NASDAQ: REGN) have received an $824 price target from Goldman Sachs. And Goldman Sachs analyst Salveen Richter initiated coverage of Regeneron Pharmaceuticals with a “Buy” rating. 

Richter is positive on Dupixent, which is expected to see strong growth trajectory and there is upside potential to projections considering the optionality from the oncology portfolio. 

Plus Richter is constructive overall on Regeneron’s science-first approach and platform value from its proprietary antibody technologies.

Disclaimer: This content is intended for informational purposes. Before making any investment, you should do your own analysis.